C

Cresilon

Plant-based hemostatic gel for bleeding control

Research & Development Manager - Polymer Formulation

Full-TimeUpdated on 10/23/2026
$130k - $180k/yr
Expert
Master's, PhD
Brooklyn, NY, USA
In PersonFull-time, on-site position in Brooklyn, New York.
Biology & BiotechBioprocess & Biomanufacturing

About the job

Requirements
  • A master's degree in Chemistry, Materials Science, Chemical Engineering, Polymer Science, or a closely equivalent discipline is required.
  • At least 10 years of research experience developing and utilizing polymeric materials, biomaterials, or other complex materials for product or application development and manufacture, including at least 5 years in a non-academic setting.
  • At least 2 years of direct management experience.
  • Hands-on research experience with polymers, coagulation chemistry, and materials science of complex systems, including developing structure-property-performance relationships for designing and characterizing materials.
  • Ability to solve difficult technical problems and deliver practical solutions that meet application requirements, with a fundamental understanding of the chemistry driving performance.
  • Direct experience in new product development from concept through regulatory approval and launch.
  • Ability to design experiments and analyze data using appropriate quality and statistical methodologies.
  • Ability to create and present clear, concise technical documentation based on complex information.
  • Ability to lead and inspire teams, develop and mentor individuals, and allocate resources according to portfolio priorities.
  • Strong leadership and organizational skills, attention to detail, multitasking ability, and capacity to maintain a broad view of projects, priorities, and strategies.
  • Experience working under pressure and tight timelines while maintaining priorities, focus, urgency, and delivery.
  • Working knowledge of Microsoft Office.
  • Ability to obtain appropriate vaccinations and clearance to work in an operating-room or surgical environment; work in laboratory settings; wear appropriate personal protective equipment; sit and stand; perform office and laboratory work for moderate periods; and speak, listen, and understand verbal and written communication.
  • Legal authorization to work in the United States.
Responsibilities
  • Lead, staff, and manage formulation development teams and their efforts across parallel product development opportunities to launch new commercially successful products.
  • Provide scientific leadership, monitoring, and coaching through initiation, planning, and execution of the team's activities.
  • Create and lead exploratory or product-development research focused on polymeric materials and their applications.
  • Use technical judgment to design, execute, and interpret experiments within project responsibilities, solving complex problems creatively and effectively in accordance with scientific methods and procedures.
  • Lead material, design, and process changes through the design-control process, with documented research and analyses.
  • Review and author protocols and reports, including development studies and design verification and validation activities.
  • Develop and implement investigations into new technologies and capabilities, partnering with business development to advance research-team and company objectives.
  • Lead chemical and mechanical property evaluation to assess process or formulation changes, and develop test-method capabilities for research, product development, and production testing.
  • Develop proprietary, ideally patentable intellectual property that provides competitive advantage.
  • Lead and participate in voice-of-customer laboratories and influence go-to-market strategies.
  • Interface with customers, suppliers, and internal cross-functional team members to develop specifications and coordinate prototype fabrication.
  • Work with cross-functional teams to develop, verify, and validate product designs through bench, in-vitro, and in-vivo testing and other assessments.
  • Ensure effective documentation is used throughout development, including research laboratory notebooks, design reviews, test methods, and test reports.
  • Maintain active dialogue with Regulatory Affairs as a subject matter expert on product design elements and documentation for research supporting FDA and other regulated-authority submissions.
  • Act as research liaison between R&D and Quality Control to define product specifications.
  • Maintain active dialogue with Manufacturing to support technology transfer and process development, including review of research-related documents.
  • Guide and support commercial teams, including introducing technologies through presentations, sales tools, formulations, and application data.
  • Communicate results through published scientific papers and present research at academic and industry symposia as a company representative.
  • Work with company leadership to evaluate research practices and contribute to ethical, high-quality research operations.
  • Provide other project, product, or leadership support as needed to support company objectives.
  • Remain actively involved in laboratory work, including experimental design, execution, troubleshooting, data interpretation, bench-scale formulation development, and characterization.
Desired Qualifications
  • A Ph.D. in a relevant discipline is strongly preferred.
  • Experience developing and commercializing products in a highly regulated environment.
  • Medical device development experience.
  • Expertise in using, developing, and qualifying material-characterization techniques, including rheological, thermal, mechanical, spectroscopic, microscopic, and other chemical-composition methods.
  • Strong understanding of regulatory requirements for Class II and III medical devices, including 21 CFR Part 820, cGLP/cGMP, and related standards such as ISO 13485.
  • Strong understanding of cGMP and ICH guidelines.
  • Six Sigma Green Belt or Black Belt certification.
  • Experience executing grant and publication submission strategies, with knowledge of and a strong track record in SBIR submissions to multiple agencies, including NIH and DOD.
  • Experience with project management and product lifecycle management practices, and ability to lead multiple projects simultaneously.

About the company

Cresilon makes medical devices that stop bleeding with a plant-based adhesive gel. Its main product, VETIGEL, is a fast-acting gel designed to control bleeding in veterinary patients, and Cresilon serves human trauma and surgical markets as well. The gel is applied to a wound and works to seal and promote clotting within seconds without needing manual pressure. Cresilon differentiates itself by offering a gel-based hemostat and by being among the first to target veterinary applications with a rapid, easy-to-use solution, along with direct sales and partnerships (for example, the VerticalVet Preferred Partnership) to reach clinics and hospitals. The company’s goal is to broaden the gel technology’s uses to improve wound care and save lives across veterinary, human trauma, and surgical settings.

Company Size

51-200

Company Stage

Early VC

Total Funding

$116.5M

Headquarters

New York City, New York

Founded

2010

Get referred to Cresilon

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sept. 30, 2026 TRAUMAGEL Next Generation expanded use across EMS, tactical, and hospitals.
  • Aug. 4, 2025 Vizient gave TRAUMAGEL an Innovative Technology contract nationwide.
  • June 16, 2025 McCarthy Vet opened VETIGEL sales across Canada.

What critics are saying

  • Cresilon still depends on expensive clinician training to displace gauze, clamps, and legacy hemostats.
  • In 2025, Cresilon pulled a launch after field misses, proving execution risk.
  • TRAUMAGEL remains the revenue engine; procurement stalls threaten Cresilon's runway and valuation.

What makes Cresilon unique

  • Cresilon's plant-based hydrogel stops bleeding in seconds without manual pressure or preparation.
  • TRAUMAGEL's 2026 compact syringe enables one-handed EMS use and go-bag portability.
  • VETIGEL reached 60,000 procedures worldwide and VerticalVet opened access to 1,800 members.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Health Savings Account/Flexible Spending Account
  • Disability Insurance
  • Life Insurance
  • Commuter Benefits
  • 401(k) Company Match
  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

2%

1 year growth

4%

2 year growth

3%
PR Newswire
Sep 30th, 2026
Cresilon launches compact TRAUMAGEL next-gen hemostatic gel for first responders

Brooklyn-based biotechnology company Cresilon has launched a next-generation version of its TRAUMAGEL hemostatic gel, debuting at EMS World Expo 2026 in Orlando, Florida. The new compact syringe format enables one-handed application whilst maintaining the same bleeding control technology as the original product. TRAUMAGEL is a plant-based gel that controls moderate to severe bleeding in seconds, requiring no preparation before use. The redesigned format offers a smaller footprint for tactical, prehospital and hospital settings, whilst the original version remains available. "When a trauma patient is severely bleeding, every second matters," said Joe Landolina, CEO and co-founder of Cresilon. Published clinical evidence documents successful hemorrhage control in complex traumatic injuries, with providers reporting faster application and quicker bleeding control.

The Mirror Democrat and Savanna Times-Journal
Mar 25th, 2026
Cresilon named one of the World's 50 Most Innovative Companies by Fast Company.

Cresilon named one of the World's 50 Most Innovative Companies by Fast Company. * 6 hrs ago PR Newswire NEW YORK, March 25, 2026 Ranked No. 1 in the medical devices category and No. 46 on Fast Company's World's 50 Most Innovative Companies list NEW YORK, March 25, 2026 /PRNewswire/ - Cresilon has been named to Fast Company's World's 50 Most Innovative Companies of 2026. The company ranked No. 1 in the medical devices category and No. 46 overall. This marks the second time Cresilon has earned the top spot in its category, after first being recognized in 2024. "Being named one of the World's 50 Most Innovative Companies and ranked No. 1 in medical devices again speaks to the work our team is doing every day," said Joe Landolina, co-founder and CEO of Cresilon. "We started Cresilon with a clear mission to save lives. Today, TRAUMAGEL is in the hands of first responders and trauma care providers across the country and making a real impact. This recognition reflects the progress we've made and the real-world impact our solution is having in trauma care." Since its last recognition, Cresilon has advanced its hemostatic technology and expanded its reach. TRAUMAGEL(R) received FDA clearance in August 2024 and launched nationwide in January 2025. Clinical use cases reported by critical care providers show TRAUMAGEL saved at least one life per day on average in 2025. The product is now used by first responders and hospitals across the U.S. to control bleeding quickly and help prevent death from severe blood loss, which accounts for more than 35% of prehospital deaths. By the end of 2025, TRAUMAGEL was in use across all targeted care settings, including law enforcement, fire, EMS, and hospital trauma teams. The product is also being evaluated by the U.S. military and has been fielded by select units. To support this growth, Cresilon expanded its manufacturing footprint to 55,000 square feet at its state-of-the-art biomanufacturing facility in Brooklyn. The World's Most Innovative Companies is Fast Company's hallmark franchise and one of its most anticipated editorial efforts of the year. This year's list highlights businesses shaping industry and culture through innovation. Alongside the World's 50 Most Innovative Companies, Fast Company also recognized 720 organizations across 59 sectors and regions. To determine honorees, Fast Company's editors and writers review companies driving progress across industries and regions. They evaluate thousands of submissions through a competitive process. The result is a global look at innovation, from early-stage startups to some of the most valuable companies in the world. "Our list of the Most Innovative Companies is about spotlighting organizations that don't just adapt to change. They drive it," said Brendan Vaughan, editor-in-chief of Fast Company. "The companies we honor this year are setting the pace for their industries and showing what sustained innovation can achieve." The full list of Fast Company's Most Innovative Companies honorees is available at fastcompany.com. It will also appear on newsstands beginning March 31, 2026. About Cresilon Cresilon(R) is a Brooklyn-based biotechnology company that develops, manufactures, and markets hemostatic medical devices using its proprietary hydrogel technology. The company's plant-based technology stops bleeding in seconds. Its current and future product lines target trauma care, biosurgery, and animal health. Cresilon's mission is to save lives. The company has been recognized by Fast Company as one of the World's 50 Most Innovative Companies and named an EMS World Innovation Awards winner for TRAUMAGEL. For more information, visit www.cresilon.com. SOURCE Cresilon

Industry City
Sep 10th, 2025
Park Slope biotech firm raises $17M after recent growth spurt

Cresilon raised $17 million in a late stage venture capital round following growth in both the company's footprint and distribution network in recent months.

Crain's New York Business
Sep 9th, 2025
Cresilon raises $17M after growth spurt

A Park Slope-based biotech startup, Cresilon, has raised $17 million in a late-stage venture capital round. This funding follows recent growth in the company's footprint and distribution network. It marks the third significant fundraising effort since Cresilon received FDA approval for its bleeding-stopping gel.

PR Newswire
Jun 16th, 2025
Cresilon Announces International Distribution Agreement For Vetigel With Mccarthy Vet

Revolutionary hemostatic gel for veterinary surgeons available in Canada through leading veterinary supply companyNEW YORK, June 16, 2025 /PRNewswire/ -- Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has entered into a distribution agreement for VETIGEL® to be sold directly to veterinary surgeons in Canada through McCarthy Vet, a full-service veterinary marketing, supply and distribution company exclusively serving veterinarians in the Canadian animal health industry.VETIGEL, a revolutionary plant-based hemostatic gel that instantly stops and controls bleeding, is now available for veterinarian surgeons across Canada through McCarthy Vet. The agreement with McCarthy Vet, a family-owned and operated company that has exclusively served the Canadian veterinary community for over 60 years, is Cresilon's first veterinary distribution partnership in Canada."Our partnership with McCarthy Vet will help us provide more veterinary surgeons with an innovative hemostatic gel that significantly improves the standard of care for pets and animals," said VETIGEL National Sales Manager Brittany Boysen. "VETIGEL has been used by thousands of veterinarians around the world and helps veterinary clinics and animal hospitals save time, reduce operating costs, and improve patient outcomes."Since the product's debut in 2021, veterinary surgeons across North America, Europe, and Asia have increasingly used VETIGEL as the fastest and most effective hemostatic agent when treating animals for traumatic wounds and routine and complex surgical procedures, including dental extractions, liver biopsies, tumor and mass removals, cleft palate repairs, and amputations. To date, the plant-based hemostatic gel for veterinary surgeons has been used in more than 60,000 surgical procedures worldwide.As McCarthy Vet expands its portfolio through a new partnership with VETIGEL, the company remains focused on delivering the solutions today's veterinary professionals need most. This collaboration reflects its ongoing promise to bring innovative products to market that offer meaningful clinical value, ease of use, and better outcomes for patients.As a flowable hemostatic gel, VETIGEL offers veterinary surgeons a safe and efficient way to control bleeding across a wide range of surgical procedures and wound geometries